---
figid: PMC3794713__nihms500992f2
figtitle: mTOR and MAPK pathways
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC3794713
filename: nihms500992f2.jpg
figlink: /pmc/articles/PMC3794713/figure/F2/
number: F2
caption: mTOR and MAPK pathways. Receptor tyrosine kinases (RTKs) activate Ras or
  PI3K. Ras activates the MAPK cascade of Raf (including BRAF), MEK, and ERK kinases,
  leading to cell survival, gene transcription, and proliferation. Activated PI3K
  phosphorylates PIP2 to PIP3 (Phosphatidylinositol bis- and tris- phosphate). PTEN
  dephosphorylates PIP3 to PIP2, inhibiting its signal. PIP3 activates Akt, which
  causes dissociation of TSC2 from TSC1, releasing inhibition of RHEB (Ras Homolog
  Enriched in Brain), which then activates mTORC1. Rapamycin analogues such as everolimus
  inhibit mTOR proteins. Crosstalk between MAPK and PI3K pathways is indicated (Ras/PI3K,
  ERK/mTORC1, and Akt/Raf). Adapted from Gadgeel SM, Wozniak A. Preclinical Rationale
  for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor
  Inhibitor-Resistant Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2013; with permission
  (see also).
papertitle: Translational Research in Endocrine Surgery.
reftext: Scott K. Sherman, et al. Surg Oncol Clin N Am. ;22(4):857-884.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9267817
figid_alias: PMC3794713__F2
figtype: Figure
redirect_from: /figures/PMC3794713__F2
ndex: 01dcf1f4-df0c-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3794713__nihms500992f2.html
  '@type': Dataset
  description: mTOR and MAPK pathways. Receptor tyrosine kinases (RTKs) activate Ras
    or PI3K. Ras activates the MAPK cascade of Raf (including BRAF), MEK, and ERK
    kinases, leading to cell survival, gene transcription, and proliferation. Activated
    PI3K phosphorylates PIP2 to PIP3 (Phosphatidylinositol bis- and tris- phosphate).
    PTEN dephosphorylates PIP3 to PIP2, inhibiting its signal. PIP3 activates Akt,
    which causes dissociation of TSC2 from TSC1, releasing inhibition of RHEB (Ras
    Homolog Enriched in Brain), which then activates mTORC1. Rapamycin analogues such
    as everolimus inhibit mTOR proteins. Crosstalk between MAPK and PI3K pathways
    is indicated (Ras/PI3K, ERK/mTORC1, and Akt/Raf). Adapted from Gadgeel SM, Wozniak
    A. Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal
    Growth Factor Receptor Inhibitor-Resistant Non-Small-Cell Lung Cancer. Clin Lung
    Cancer. 2013; with permission (see also).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Tie
  - Ras85D
  - InR
  - l(1)G0020
  - Taf4
  - Pi3K92E
  - Rpn2
  - Sap-r
  - Myb
  - Pi3K21B
  - Taf5
  - drk
  - Sos
  - Akt
  - Pten
  - CycE
  - cyc
  - gig
  - Tsc1
  - Rheb
  - ras
  - Ras64B
  - Crtc
  - S6k
  - Raf
  - Mtor
  - Tor
  - Dsor1
  - Mtk
  - Erk7
  - rl
  - CUX1
  - SART3
  - PIK3R1
  - PIK3R2
  - ARHGEF7
  - CBFA2T2
  - PPP1R13B
  - PPP1R12C
  - GRB2
  - XYLT2
  - SOS1
  - SOS2
  - AKT1
  - AKT2
  - AKT3
  - PTEN
  - TSC2
  - TSC1
  - CCL26
  - RHEB
  - RHEBP1
  - KRAS
  - HRAS
  - NRAS
  - MTOR
  - RPTOR
  - MAPKAP1
  - RICTOR
  - MLST8
  - RPS6KB1
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - Glucose
  - Rapamycin
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
